BridgeBio Pharma, Inc. — Director's Dealing 2020

Jul 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-30

Reporting Person: Turtle Cameron (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-30	Common Stock	M	6000	$0.16	Acquired	15823	Direct
2020-06-30	Common Stock	M	4000	$0.34	Acquired	19823	Direct
2020-06-30	Common Stock	S	9700	$32.6465	Disposed	10123	Direct
2020-06-30	Common Stock	S	300	$33.1733	Disposed	9823	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-30	Stock Option (Right to Buy)	$0.16	M	6000	Disposed	2029-05-23	Common Stock (6000)	Direct
2020-06-30	Stock Option (Right to Buy)	$0.34	M	4000	Disposed	2029-07-14	Common Stock (4000)	Direct

Footnotes

F1: Represents the weighted average sale price of the shares sold from $32.12 to $33.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2.

F2: Represents the weighted average sale price of the shares sold from $33.13 to $33.23 per share.